Results
VULVOVAGINAL SIGNS AND SYMPTOMS
A total of 376 patients from the United States were randomly assigned to receive ibrexafungerp (Patient disposition of the pooled analysis of the VANISH 303 and VANISH 306 studies. Demographics and baseline characteristics of the mITT population are presented in Patient Characteristics and Demographics (Modified Intention to Treat Population)Included multiracial patients and patients in whom a race was not identified.Women may have had more than one Other species in the ibrexafungerp versus placebo groups, respectively, included BID, twice daily; BMI, body mass index; max, maximum; min, minimum; mITT, modified intention to treat; VSS, vulvovaginal signs and symptoms.